FibroGen (FGEN) Tops Q3 EPS by 14c, Misses on Revenue; Offers FY24 Revenue Guidance

FibroGen (NASDAQ: FGEN) reported Q3 EPS of ($0.17), $0.14 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $46.3 million versus the consensus estimate of $34.84 million.

GUIDANCE:

FibroGen sees FY2024 revenue of $135-150 million, versus the consensus of $174.4 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• RoundHill T-Rex 2X Long (RAM) call put ratio 2.7 calls to 1 put on active option volume of 23K contracts as share price up 9.8%
• Western Digital (WDC) call put ratio 1 call to 1.2 puts on 57K contracts